Capital Investment Advisors LLC Has $465,000 Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Capital Investment Advisors LLC boosted its stake in Becton, Dickinson and Company (NYSE:BDX) by 4.8% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 2,030 shares of the medical instruments supplier’s stock after buying an additional 93 shares during the period. Capital Investment Advisors LLC’s holdings in Becton, Dickinson and Company were worth $465,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. grew its stake in Becton, Dickinson and Company by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 26,743,052 shares of the medical instruments supplier’s stock valued at $6,067,196,000 after buying an additional 184,288 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its stake in Becton, Dickinson and Company by 36.1% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 12,126,707 shares of the medical instruments supplier’s stock valued at $2,751,187,000 after buying an additional 3,219,317 shares during the last quarter. Geode Capital Management LLC grew its stake in Becton, Dickinson and Company by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 6,351,537 shares of the medical instruments supplier’s stock valued at $1,437,161,000 after buying an additional 66,024 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in Becton, Dickinson and Company by 15.1% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 6,175,899 shares of the medical instruments supplier’s stock valued at $1,401,126,000 after buying an additional 810,345 shares during the last quarter. Finally, First Eagle Investment Management LLC grew its stake in Becton, Dickinson and Company by 31.4% in the 4th quarter. First Eagle Investment Management LLC now owns 4,426,022 shares of the medical instruments supplier’s stock valued at $1,004,132,000 after buying an additional 1,057,879 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $174.21 on Wednesday. The company has a 50 day moving average of $184.92 and a 200-day moving average of $214.07. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. The company has a market cap of $49.93 billion, a PE ratio of 28.94, a price-to-earnings-growth ratio of 1.63 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, topping analysts’ consensus estimates of $3.28 by $0.07. The company had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.35 billion. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.17 EPS. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 30th. Investors of record on Monday, June 9th will be paid a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 2.39%. The ex-dividend date of this dividend is Monday, June 9th. Becton, Dickinson and Company’s payout ratio is 79.39%.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 479 shares of the company’s stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total value of $94,497.12. Following the completion of the transaction, the executive vice president now directly owns 4,887 shares in the company, valued at approximately $964,107.36. This represents a 8.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP David Shan sold 1,166 shares of the company’s stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the transaction, the executive vice president now owns 4,575 shares of the company’s stock, valued at approximately $783,194.25. This trade represents a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,104 shares of company stock valued at $399,675 in the last quarter. Insiders own 0.36% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Bank of America downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 price objective for the company. in a report on Thursday, May 1st. Citigroup downgraded shares of Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and cut their price objective for the company from $217.00 to $185.00 in a report on Thursday, May 22nd. Stifel Nicolaus cut their price objective on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a “buy” rating for the company in a report on Friday, May 2nd. Morgan Stanley cut their price objective on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an “overweight” rating for the company in a report on Tuesday, May 6th. Finally, Raymond James downgraded shares of Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a report on Friday, May 2nd. Eight investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $219.22.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.